161386-60-3

Upstream product

• 403-42-9 1-(4-fluorophenyl)ethanone 
• 161386-86-3 2-mercapto-4-[(2S)-2,2,4-trimethyl-1,3-dioxolan-4-yl]-thiophene 
• 3814-20-8 4-mercaptoacetophenone 
• 1778-09-2 4-(Methylthio)acetophenone 
• 5335-82-0 1,1'-(disulfane-1,2-diylbis(4,1-phenylene))bis(ethan-1-one) 
• 171285-71-5 2,2,4-Trimethyl-4-thiophen-3-yl-[1,3]dioxolane 
• 159615-90-4 2-(5-Methylsulfanyl-thiophen-3-yl)-1-(tetrahydro-pyran-2-yloxy)-propan-2-ol 
• 156538-37-3 4'-(4-bromothien-2-ylthio)acetophenone ethylene acetal 
• 156538-36-2 bis<4-(2-methyl-1,3-dioxolan-2-yl)phenyl> disulfide 
• 161386-57-8 4'-[4-(2-hydroxy-1-tetrahydropyran-2-yloxyprop-2-yl)thien-2-ylthio]acetophenone ethylene acetal 
• 161386-84-1 4-(2,3-dihydroxyprop-2-yl)-2-(methylthio)thiophene 
• 161386-85-2 2-(methylthio)-4-(2,2,4-trimethyl-1,3-dioxolan-4-yl)thiophene 

Relevant academic research and scientific papers

Chiral Dioxolane Inhibitors of Leukotriene Biosynthesis: Structure-Activity Relationships and Syntheses Using Asymmetric Dihydroxylation

1,3-Dioxolanes have been described as chiral inhibitors of 5-lipoxygenase (5LO).In the present work, this series has been developed further to provide agents which showed comparable or superior potency in vivo to ZD2138, a methoxytetrahydropyran inhibitor of 5LO, which is currently undergoing clinical evaluation.An asymmetric synthesis was developed to these dioxolanes based on asymmetric dihydroxylation. (S)-N-Methyl-4'-thio>acetanilide ((S)-10d) inhibited leukotriene B4 (LTB4) synthesis in A23187-stimulated human whole blood in vitro with IC50 0.039μM, 25-fold more potent than (R)-10d.In vivo, (S)-10d inhibited LTB4 synthesis by 70percent in zymosan-inflamed air pouch exudate in rat 10 h after an oral dose of 1.5 mg/kg.Structure-activity relationship considerations suggested that the dioxolane and methoxytatrahydropyran series are related, a conclusion which can be supported by molecular modeling.